UCB SA (OTCMKTS:UCBJY – Get Free Report)’s share price crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $97.68 and traded as low as $90.34. UCB shares last traded at $91.24, with a volume of 23,999 shares.
UCB Price Performance
The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The stock has a 50-day simple moving average of $97.68 and a 200 day simple moving average of $95.21.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
- Five stocks we like better than UCB
- How to Plot Fibonacci Price Inflection Levels
- How to Protect Your Portfolio When Inflation Is Rising
- Investing In Preferred Stock vs. Common Stock
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- 3 Tickers Leading a Meme Stock Revival
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
